aTyr Pharma’s Phase 3 Sarcoidosis Drug Misses Primary Endpoint
aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase…
MIPLYFFA Shows 5-Year Disease Stability in Niemann-Pick Type C Treatment Study
Zevra Therapeutics (NASDAQ:ZVRA) announced the presentation of four posters at…